Neimeth International Pharmaceuticals Plc (NGX:NEIMETH)
Nigeria flag Nigeria · Delayed Price · Currency is NGN
12.60
-0.30 (-2.33%)
At close: Feb 12, 2026

NGX:NEIMETH Income Statement

Millions NGN. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Sep '22
7,3694,4852,2102,9192,703
Revenue Growth (YoY)
64.29%102.98%-24.31%8.01%-11.29%
Cost of Revenue
4,0562,5501,5001,8861,629
Gross Profit
3,3131,936709.151,0331,074
Selling, General & Admin
1,7481,2861,6361,2041,125
Other Operating Expenses
-94.42-1,183-1,225-157.95-26.15
Operating Expenses
1,653103.7410.421,0461,099
Operating Income
1,6601,832298.73-12.39-24.8
Interest Expense
-1,223-873.32-667.95-300-181.77
Interest & Investment Income
249.57231.39129.23--
Currency Exchange Gain (Loss)
48.11-2,048-1,4511.9496.89
EBT Excluding Unusual Items
733.87-858.03-1,691-310.45-109.67
Gain (Loss) on Sale of Assets
1.213.60.97--
Asset Writedown
752.97----
Pretax Income
1,488-854.43-1,690-310.44-109.66
Income Tax Expense
505.9430.9107.8814.6-
Net Income
982.11-885.33-1,798-325.04-109.66
Net Income to Common
982.11-885.33-1,798-325.04-109.66
Shares Outstanding (Basic)
4,2734,2734,2731,8991,899
Shares Outstanding (Diluted)
4,2734,2734,2731,8991,899
Shares Change (YoY)
--125.00%--
EPS (Basic)
0.23-0.21-0.42-0.17-0.06
EPS (Diluted)
0.23-0.21-0.42-0.17-0.06
Free Cash Flow
-3,627-306.71-1,710-1,137-1,205
Free Cash Flow Per Share
-0.85-0.07-0.40-0.60-0.63
Gross Margin
44.96%43.16%32.09%35.39%39.74%
Operating Margin
22.52%40.84%13.52%-0.43%-0.92%
Profit Margin
13.33%-19.74%-81.35%-11.13%-4.06%
Free Cash Flow Margin
-49.23%-6.84%-77.37%-38.95%-44.57%
EBITDA
1,8241,962424.8296.0294.78
EBITDA Margin
24.76%43.74%19.23%3.29%3.51%
D&A For EBITDA
164.92129.99126.09108.41119.57
EBIT
1,6601,832298.73-12.39-24.8
EBIT Margin
22.52%40.84%13.52%-0.42%-0.92%
Effective Tax Rate
34.00%----
Advertising Expenses
122.32192.93363.67-188.49
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.